FDA Approves GADAVIST — Bayer HealthCare Pharmaceuticals Inc.

# FDA Approves Bayer's Gadavist (Gadobutrol) for MRI Contrast Imaging Bayer HealthCare Pharmaceuticals Inc. received FDA approval for Gadavist (gadobutrol), an intravenous contrast agent for magnetic resonance imaging, positioning the company to capture market share in the competitive diagnostic imaging sector. The approval expands Bayer's portfolio in contrast-enhanced MRI and offers healthcare providers an additional option for improving image quality in neurological and cardiovascular diagnostic procedures.